|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2011-6-13
|
|
pubmed:abstractText |
The site of pharmacological activity of raltegravir is intracellular. Our aim was to determine the extent of raltegravir cellular penetration and whether raltegravir total plasma concentration (C(tot)) predicts cellular concentration (C(cell)).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1460-2091
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1573-81
|
|
pubmed:meshHeading |
pubmed-meshheading:21508009-Adult,
pubmed-meshheading:21508009-Aged,
pubmed-meshheading:21508009-Anti-HIV Agents,
pubmed-meshheading:21508009-Chromatography, Liquid,
pubmed-meshheading:21508009-Cytoplasm,
pubmed-meshheading:21508009-Female,
pubmed-meshheading:21508009-HIV Infections,
pubmed-meshheading:21508009-Humans,
pubmed-meshheading:21508009-Leukocytes, Mononuclear,
pubmed-meshheading:21508009-Male,
pubmed-meshheading:21508009-Mass Spectrometry,
pubmed-meshheading:21508009-Middle Aged,
pubmed-meshheading:21508009-Plasma,
pubmed-meshheading:21508009-Prospective Studies,
pubmed-meshheading:21508009-Pyrrolidinones
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
|
|
pubmed:affiliation |
Division of Clinical Pharmacology and Toxicology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
